USP14 and pancreatic ductal adenocarcinoma: Aberrant expression of USP14 is associated with progression of various cancers, including colorectal carcinoma 26, hepatocellular carcinoma 44, pancreatic ductal adenocarcinoma 27, breast cancer 45, and gastric cancer 46.